KIRhub 2.0· v2

Sorafenib

6754d06f-33d3-5d11-b1c0-4d14ccbf2e06 · FDA Approved · targets FLT1_VEGFR1, FLT4_VEGFR3, KDR_VEGFR2

Sorafenib

MeasuredReference

Sorafenib targets RAF1, ARAF, BRAF. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

RAF1 ARAF BRAF HIPK4 C_KIT

Top hallmarks

tumor promoting inflammation1.7k
proliferation1.6k
evading apoptosis1.4k

Top pathways disrupted

pi3k akt mtor signaling4.1k
apical junction3.8k
apoptosis2.7k

Resistance landscape — Sorafenib

MeasuredReference

10 known oncogenic variants exist on Sorafenib's top targets — see detail for inhibition impact.

RAF1 1 known variant
- RAF1 (R391W)
BRAF 9 known variants

Open in new tab